SEC Form 4 · accession 0000899243-16-021419

REATA PHARMACEUTICALS INC · RETA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks · Director

Period of report

Jun 1, 2016

Accepted (ET)

Jun 2, 2016 · 6:18 am EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001358762

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A common stock^F1	Jun 1, 2016	C	62,657	—	A	62,657	D
Class A common stock	Jun 1, 2016	P	114,000	$11.00	A	176,657	D
Class A common stock^F1	Jun 1, 2016	C	3,166	—	A	3,166	I	By Huff 2010 Descendants' Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Class B common stock^F1	—	Jun 1, 2016	C	62,567	D	—	—	Class A common stock	62,567	700,806	D
Class B common stock^F1	—	Jun 1, 2016	C	3,166	D	—	—	Class A common stock	3,166	35,234	I

F1The Class B common stock is convertible into Class A common stock on a one-for-one basis (a) at the holder's election at any time after the date that is six months following the date of the closing of the initial public offering of the company's Class A common stock, (b) at the holder's election prior to that time subject to certain conditions, or (c) at the option of the company's board of directors, in its sole discretion, at any time or multiple times from time to time on or before the closing of the initial public offering. The conversion right of the Class B common stock has no expiration date.

Chief Executive Officer, President, and Chairman of the Board of Directors